Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 3
2018 5
2019 5
2020 5
2021 10
2022 10
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
Bernardi M, Ferrara F, Carrabba MG, Mastaglio S, Lorentino F, Vago L, Ciceri F. Bernardi M, et al. Among authors: lorentino f. Front Oncol. 2022 Jul 18;12:890871. doi: 10.3389/fonc.2022.890871. eCollection 2022. Front Oncol. 2022. PMID: 35924144 Free PMC article. Review.
Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients.
Noviello M, Lorentino F, Xue E, Racca S, Furnari G, Valtolina V, Campodonico E, Dvir R, Lupo-Stanghellini MT, Giglio F, Piemontese S, Clerici D, Oltolini C, Tassi E, Beretta V, Farina F, Mannina D, Ardemagni A, Vago L, Bernardi M, Corti C, Peccatori J, Clementi M, Ciceri F, Bonini C, Greco R. Noviello M, et al. Among authors: lorentino f. Blood Adv. 2023 Sep 26;7(18):5446-5457. doi: 10.1182/bloodadvances.2022009274. Blood Adv. 2023. PMID: 37067947 Free PMC article.
Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation.
Tassi E, Noviello M, De Simone P, Lupo-Stanghellini MT, Doglio M, Serio F, Abbati D, Beretta V, Valtolina V, Oliveira G, Racca S, Campodonico E, Ruggiero E, Clerici D, Giglio F, Lorentino F, Dvir R, Xue E, Farina F, Oltolini C, Manfredi F, Vago L, Corti C, Bernardi M, Clementi M, Brix L, Ciceri F, Peccatori J, Greco R, Bonini C. Tassi E, et al. Among authors: lorentino f. Haematologica. 2023 Jun 1;108(6):1530-1543. doi: 10.3324/haematol.2022.280685. Haematologica. 2023. PMID: 36200418 Free PMC article.
Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients.
Xue E, Lorentino F, Clerici D, Farina F, Oltolini C, Giglio F, Campodonico E, Nitti R, Bernardi M, Corti C, Peccatori J, Ciceri F, Lupo Stanghellini MT, Greco R. Xue E, et al. Among authors: lorentino f. Bone Marrow Transplant. 2022 Jan;57(1):128-130. doi: 10.1038/s41409-021-01486-5. Epub 2021 Oct 8. Bone Marrow Transplant. 2022. PMID: 34625664 No abstract available.
Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation.
Lorentino F, Xue E, Mastaglio S, Giglio F, Clerici D, Farina F, Piemontese S, Bruno A, Lazzari L, Ruggeri A, Guggiari E, Lunghi F, Assanelli AA, Marktel S, Marcatti M, Carrabba MG, Bernardi M, Corti C, Peccatori J, Ciceri F, Greco R, Lupo-Stanghellini MT. Lorentino F, et al. Blood Adv. 2022 May 24;6(10):3053-3057. doi: 10.1182/bloodadvances.2021006213. Blood Adv. 2022. PMID: 35078219 Free PMC article. No abstract available.
Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients.
Greco R, Nitti R, Mancini N, Pasciuta R, Lorentino F, Lupo-Stanghellini MT, Barbanti MC, Clementi N, Giglio F, Clerici D, Marktel S, Assanelli A, Carrabba MG, Bernardi M, Corti C, Peccatori J, Clementi M, Ciceri F. Greco R, et al. Among authors: lorentino f. Blood. 2021 Mar 18;137(11):1556-1559. doi: 10.1182/blood.2020007158. Blood. 2021. PMID: 33171492 Free article. No abstract available.
Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, Xue E, Farina F, Pavesi F, Assanelli A, Carrabba MG, Marktel S, Vago L, Bonini C, Corti C, Bernardi M, Ciceri F, Peccatori J. Greco R, et al. Among authors: lorentino f. Transplant Cell Ther. 2021 Sep;27(9):776.e1-776.e13. doi: 10.1016/j.jtct.2021.05.023. Epub 2021 Jun 1. Transplant Cell Ther. 2021. PMID: 34087452 Free article.
Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up.
Lupo-Stanghellini MT, Piemontese S, Assanelli A, Serpenti F, Mastaglio S, Clerici D, Giglio F, Greco R, Lorentino F, Pavesi F, Farina F, Marktel S, Corti C, Peccatori J, Ciceri F. Lupo-Stanghellini MT, et al. Among authors: lorentino f. Hemasphere. 2021 Oct 28;5(11):e654. doi: 10.1097/HS9.0000000000000654. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34901758 Free PMC article. No abstract available.
Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis.
Ardizzoia F, Lorentino F, Bruno A, Marktel S, Giglio F, Clerici D, Farina F, Mastaglio S, Piemontese S, Assanelli AA, Carrabba MG, Bernardi M, Corti C, Peccatori J, Ciceri F, Greco R, Lupo-Stanghellini MT. Ardizzoia F, et al. Among authors: lorentino f. Haematologica. 2022 Nov 1;107(11):2748-2751. doi: 10.3324/haematol.2022.281269. Haematologica. 2022. PMID: 35899390 Free PMC article. No abstract available.
40 results